EryDel SpA, a biotech company specializing in the development and commercialization of drugs and diagnostics delivered through autologous red blood cells, announced the appointment of Ronan W. Gannon as Chief Commercial Officer, effective immediately.
“I am pleased to welcome Ronan to EryDel,” said Dr. Luca Benatti, Chief Executive Officer of EryDel.
Ronan’s commercial expertise in rare diseases and blood products will be critical as we advance our comprehensive development program for EryDex, including our pivotal Phase 3 clinical study (ATTeST) in Ataxia Telangiectasia and seek to transition EryDel from a late-stage research and development company to a commercial-stage organization.
We look forward to his contribution as a member of our leadership team.” Ronan brings more than 25 years of industry experience across large, midsize and startup life science companies.
Before joining EryDel, Ronan led global commercial operations at Radius Health, where he helped transform the company from a late-stage development startup into a fully integrated biopharmaceutical company. Prior to that, Ronan spent ten years at CSL Behring where he held several leadership roles including US Vice President Marketing and North America general management roles in the US and Canada. During his tenure at CSL Behring he launched six orphan drugs. Prior to CSL, Ronan led sales and marketing teams at Zeneca Pharmaceuticals, and GlaxoSmithKline across several therapeutic areas including biologicals, oncology, and asthma. He received an MBA from Northeastern University, a BA from the University of Richmond and holds alumni status from the Harvard Business School.
"I am delighted to join EryDel as the company begins planning for the commercialization of EryDex,“ said Mr. Gannon. “EryDel has played a significant role in developing an innovative treatment for Ataxia Telangiectasia, a life-threatening disease. I look forward to working with the team to continue ongoing community and market development efforts, and to advance a robust commercialization strategy for the launch of EryDex.”